LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process

Stock News

01/07

LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1153150074"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153150074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153150074?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153150074","market":"other","top_or_hot":-1,"title":"LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-07 18:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"麗珠醫藥","start_time":0,"source_url":"","article_id":"1153150074","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153150074","pubTimestamp":1767782761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药","BK1191":"制药"},"translate_title":"丽珠医药(01513)：莱康奇他单抗注射液纳入优先审评审批程序","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}